CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 128 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2013. The put-call ratio across all filers is 1.26 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $141,000 | -69.3% | 279,320 | +851.7% | 0.00% | -50.0% |
| Q4 2015 | $460,000 | -56.7% | 29,350 | -30.3% | 0.00% | -60.0% |
| Q2 2015 | $1,062,000 | -14.9% | 42,100 | -6.0% | 0.01% | -28.6% |
| Q1 2015 | $1,248,000 | -59.0% | 44,773 | -74.0% | 0.01% | -76.7% |
| Q1 2014 | $3,047,000 | +440.2% | 172,441 | +377.6% | 0.03% | +400.0% |
| Q2 2013 | $564,000 | – | 36,105 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| KLP Enterprises, LLC | 6,865,006 | $24,302,000 | 100.00% |
| TSP Capital Management Group, LLC | 886,398 | $3,138,000 | 1.60% |
| Marcus Capital, LLC | 109,950 | $389,000 | 0.42% |
| RTW INVESTMENTS, LP | 239,662 | $848,000 | 0.32% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 6,195,855 | $21,933,000 | 0.31% |
| Benchmark Capital Advisors | 66,800 | $236,000 | 0.20% |
| Bellevue Group AG | 160,000 | $566,000 | 0.12% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 632,944 | $2,241,000 | 0.09% |
| PDT Partners, LLC | 369,300 | $1,307,000 | 0.09% |
| Vident Investment Advisory, LLC | 196,715 | $696,000 | 0.08% |